Literature DB >> 10594467

Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo.

J T Larsen1, L L Hansen, K Brosen.   

Abstract

AIMS: The aim of the present study was to examine the CYP1A2 substrate tacrine as a possible alternative to caffeine for assessing CYP1A2 activity in vivo.
METHODS: Eighteen, healthy, nonsmoking men participated. Each volunteer was tested by caffeine (200 mg orally), and caffeine metabolic ratios were calculated. Subsequently, on two occasions, separated by at least 4 weeks, each volunteer was tested with tacrine (40 mg orally). The apparent oral clearance, partial clearances and different metabolic ratios of tacrine were determined.
RESULTS: The median oral clearances of tacrine in the two study periods were 1893 l h-1 (range: 736-3098) and 1890 l h-1 (range: 438-4175), respectively. The interindividual coefficient of variation was 42% and 49%, respectively. The intraindividual coefficients of variation ranged from 0.28% to 64% (median: 13%). In both study periods, the oral clearance of tacrine correlated with the caffeine urinary metabolic ratio. However, only modest magnitudes of correlation were observed (rs: 0.64-0.66, P<0. 01). No tacrine metabolic ratio correlating with the oral clearance of tacrine was found. Conclusion The applicability of tacrine as a probe drug for measuring CYP1A2 activity in vivo appears limited.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594467      PMCID: PMC2014350          DOI: 10.1046/j.1365-2125.1999.00079.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  33 in total

1.  Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo.

Authors:  J T Larsen; L L Hansen; O Spigset; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1999-07       Impact factor: 2.953

Review 2.  The use of caffeine for enzyme assays: a critical appraisal.

Authors:  W Kalow; B K Tang
Journal:  Clin Pharmacol Ther       Date:  1993-05       Impact factor: 6.875

3.  A urinary metabolite ratio that reflects systemic caffeine clearance.

Authors:  M E Campbell; S P Spielberg; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1987-08       Impact factor: 6.875

4.  Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities.

Authors:  W Kalow; B K Tang
Journal:  Clin Pharmacol Ther       Date:  1991-11       Impact factor: 6.875

5.  Fluvoxamine is a potent inhibitor of cytochrome P4501A2.

Authors:  K Brøsen; E Skjelbo; B B Rasmussen; H E Poulsen; S Loft
Journal:  Biochem Pharmacol       Date:  1993-03-24       Impact factor: 5.858

6.  An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes.

Authors:  S Madden; T F Woolf; W F Pool; B K Park
Journal:  Biochem Pharmacol       Date:  1993-07-06       Impact factor: 5.858

7.  Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine.

Authors:  K Vistisen; H E Poulsen; S Loft
Journal:  Carcinogenesis       Date:  1992-09       Impact factor: 4.944

8.  Intra-individual variability of caffeine elimination in healthy subjects.

Authors:  A Balogh; S Harder; R Vollandt; A H Staib
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1992-10

9.  Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe.

Authors:  V Spaldin; S Madden; D A Adams; R J Edwards; D S Davies; B K Park
Journal:  Drug Metab Dispos       Date:  1995-09       Impact factor: 3.922

10.  Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.

Authors:  A Lemoine; J C Gautier; D Azoulay; L Kiffel; C Belloc; F P Guengerich; P Maurel; P Beaune; J P Leroux
Journal:  Mol Pharmacol       Date:  1993-05       Impact factor: 4.436

View more
  1 in total

1.  NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.

Authors:  A Nyéki; T Buclin; J Biollaz; L A Decosterd
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.